Earnings History Data for Cardiff Oncology, Inc. (CRDF) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Cardiff Oncology, Inc.
Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29-02-2024 | AH | CRDF | Cardiff Oncology, Inc. | 76.40 | -0.21 | -0.26 | -0.20 | Cardiff Oncology GAAP EPS of -$0.93 beats by $0.08, revenue of $0.48M beats by $0.2M [2/29/2024 4:10 PM] |
2.95 | 1.18 (67.13%) |
2.01 | 0.24 (13.88%) |
0.94 - 3.07 | 40,107,518 | 310,000 | 4,091,155 | ||
| 09-08-2023 | AH | CRDF | Cardiff Oncology | 70.00 | -0.25 | -0.27 | 0.00 | Cardiff Oncology GAAP EPS of -$0.25 beats by $0.01, revenue of $0.11M beats by $0.05M [8/9/2023 5:28 PM] |
2.06 | 0.15 (7.85%) |
2.00 | 0.09 (4.71%) |
1.20 - 3.31 | 923,504 | 2,590,000 | 11,557 | ||
| 05-08-2021 | AH | 4:10 PM ET (Aug 5) |
CRDF | Cardiff Oncology, Inc. | 193.00 | -0.17 | -0.15 | 0.00 | Cardiff Oncology EPS misses by $0.02, misses on revenue [8/5/2021 5:38 PM] |
5.76 | 0.61 (11.75%) |
5.23 | 0.08 (1.55%) |
4.50 - 25.50 | 986,798 | 660,000 | 5,122 | |
| 06-05-2021 | AH | 4:10 PM ET (May 6) |
CRDF | Cardiff Oncology, Inc. | 342.00 | -0.14 | -0.14 | 0.00 | Cardiff Oncology EPS beats by $0.01, misses on revenue [5/6/2021 5:24 PM] |
9.49 | 0.48 (5.33%) |
9.01 | 0.0 (0.00%) |
0.82 - 25.50 | 741,900 | 800,000 | 738 | |
| 25-02-2021 | AH | CRDF | Cardiff Oncology, Inc. | 362.78 | -0.19 | -0.15 | -0.51 | Cardiff Oncology EPS misses by $0.05, beats on revenue [2/25/2021 5:20 PM] |
10.34 | 0.59 (6.05%) |
9.90 | 0.15 (1.54%) |
0.70 - 25.50 | 3,098,438 | 1,664,415 | 7,317 | ||
| 05-11-2020 | AH | 4:15 PM ET (Nov 5) |
CRDF | Cardiff Oncology, Inc. | 523.22 | -0.19 | -0.20 | -0.71 | Cardiff Oncology EPS in-line, beats on revenue [11/5/2020 5:10 PM] |
18.11 | 1.11 (6.53%) |
17.00 | 0.0 (0.00%) |
0.70 - 18.97 | 1,015,055 | 867,432 | 1,125 | |
|
|
||||||||||||||||||